Selected research
Industry Research
Platinum Anti-tumor Drugs Industry Research Report 2026
Market perspective
The global Platinum Anti-tumor Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Platinum Anti-tumor Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Platinum Anti-tumor Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Platinum Anti-tumor Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Platinum Anti-tumor Drugs include Teva, Sun Pharma, Sanofi, Novartis, Pfizer, Hengrui Medicine, Yi Bai Pharmaceutical, Viatris and SK Chemicals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Platinum Anti-tumor Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Platinum Anti-tumor Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Platinum Anti-tumor Drugs Market by Company
Teva
Sun Pharma
Sanofi
Novartis
Pfizer
Hengrui Medicine
Yi Bai Pharmaceutical
Viatris
SK Chemicals
Qilu Pharmaceutical
Dr Reddy's Laboratories
Debiopharm
ASK Pharma
Accord Healthcare
Platinum Anti-tumor Drugs Segment by Type
Oxaliplatin
Carboplatin
Cisplatin
Other
Platinum Anti-tumor Drugs Segment by Application
Ovarian Cancer
Lung Cancer
Colorectal Cancer
Other
Platinum Anti-tumor Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum Anti-tumor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Platinum Anti-tumor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum Anti-tumor Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Platinum Anti-tumor Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oxaliplatin
- Carboplatin
- Cisplatin
- Other
Applications
- Ovarian Cancer
- Lung Cancer
- Colorectal Cancer
- Other
Companies covered
- Teva
- Sun Pharma
- Sanofi
- Novartis
- Pfizer
- Hengrui Medicine
- Yi Bai Pharmaceutical
- Viatris
- SK Chemicals
- Qilu Pharmaceutical
- Dr Reddy's Laboratories
- Debiopharm
- ASK Pharma
- Accord Healthcare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Platinum Anti-tumor Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oxaliplatin
- 2.2.3 Carboplatin
- 2.2.4 Cisplatin
- 2.2.5 Other
- 2.3 Platinum Anti-tumor Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Ovarian Cancer
- 2.3.3 Lung Cancer
- 2.3.4 Colorectal Cancer
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Platinum Anti-tumor Drugs Breakdown Data by Type
- 3.1 Global Platinum Anti-tumor Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Platinum Anti-tumor Drugs Forecasted Market Size by Type (2027-2032)
4 Platinum Anti-tumor Drugs Breakdown Data by Application
- 4.1 Global Platinum Anti-tumor Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Platinum Anti-tumor Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Platinum Anti-tumor Drugs Market Perspective (2021-2032)
- 5.2 Global Platinum Anti-tumor Drugs Growth Trends by Region
- 5.2.1 Global Platinum Anti-tumor Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Platinum Anti-tumor Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Platinum Anti-tumor Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Platinum Anti-tumor Drugs Market Dynamics
- 5.3.1 Platinum Anti-tumor Drugs Industry Trends
- 5.3.2 Platinum Anti-tumor Drugs Market Drivers
- 5.3.3 Platinum Anti-tumor Drugs Market Challenges
- 5.3.4 Platinum Anti-tumor Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Platinum Anti-tumor Drugs Players by Revenue
- 6.1.1 Global Top Platinum Anti-tumor Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Platinum Anti-tumor Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Platinum Anti-tumor Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Platinum Anti-tumor Drugs Head Office and Area Served
- 6.4 Global Platinum Anti-tumor Drugs Players, Product Type & Application
- 6.5 Global Platinum Anti-tumor Drugs Manufacturers Established Date
- 6.6 Global Platinum Anti-tumor Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Platinum Anti-tumor Drugs Market Size (2021-2032)
- 7.2 North America Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 7.4 North America Platinum Anti-tumor Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Platinum Anti-tumor Drugs Market Size (2021-2032)
- 8.2 Europe Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 8.4 Europe Platinum Anti-tumor Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Platinum Anti-tumor Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Platinum Anti-tumor Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Platinum Anti-tumor Drugs Market Size (2021-2032)
- 10.2 South America Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 10.4 South America Platinum Anti-tumor Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Platinum Anti-tumor Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Platinum Anti-tumor Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Platinum Anti-tumor Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva
- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.1.4 Teva Platinum Anti-tumor Drugs Product Portfolio
- 12.1.5 Teva Recent Developments
- 12.2 Sun Pharma
- 12.2.1 Sun Pharma Company Information
- 12.2.2 Sun Pharma Business Overview
- 12.2.3 Sun Pharma Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.2.4 Sun Pharma Platinum Anti-tumor Drugs Product Portfolio
- 12.2.5 Sun Pharma Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.3.4 Sanofi Platinum Anti-tumor Drugs Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.4.4 Novartis Platinum Anti-tumor Drugs Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.5.4 Pfizer Platinum Anti-tumor Drugs Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 Hengrui Medicine
- 12.6.1 Hengrui Medicine Company Information
- 12.6.2 Hengrui Medicine Business Overview
- 12.6.3 Hengrui Medicine Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.6.4 Hengrui Medicine Platinum Anti-tumor Drugs Product Portfolio
- 12.6.5 Hengrui Medicine Recent Developments
- 12.7 Yi Bai Pharmaceutical
- 12.7.1 Yi Bai Pharmaceutical Company Information
- 12.7.2 Yi Bai Pharmaceutical Business Overview
- 12.7.3 Yi Bai Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.7.4 Yi Bai Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
- 12.7.5 Yi Bai Pharmaceutical Recent Developments
- 12.8 Viatris
- 12.8.1 Viatris Company Information
- 12.8.2 Viatris Business Overview
- 12.8.3 Viatris Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.8.4 Viatris Platinum Anti-tumor Drugs Product Portfolio
- 12.8.5 Viatris Recent Developments
- 12.9 SK Chemicals
- 12.9.1 SK Chemicals Company Information
- 12.9.2 SK Chemicals Business Overview
- 12.9.3 SK Chemicals Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.9.4 SK Chemicals Platinum Anti-tumor Drugs Product Portfolio
- 12.9.5 SK Chemicals Recent Developments
- 12.10 Qilu Pharmaceutical
- 12.10.1 Qilu Pharmaceutical Company Information
- 12.10.2 Qilu Pharmaceutical Business Overview
- 12.10.3 Qilu Pharmaceutical Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.10.4 Qilu Pharmaceutical Platinum Anti-tumor Drugs Product Portfolio
- 12.10.5 Qilu Pharmaceutical Recent Developments
- 12.11 Dr Reddy's Laboratories
- 12.11.1 Dr Reddy's Laboratories Company Information
- 12.11.2 Dr Reddy's Laboratories Business Overview
- 12.11.3 Dr Reddy's Laboratories Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.11.4 Dr Reddy's Laboratories Platinum Anti-tumor Drugs Product Portfolio
- 12.11.5 Dr Reddy's Laboratories Recent Developments
- 12.12 Debiopharm
- 12.12.1 Debiopharm Company Information
- 12.12.2 Debiopharm Business Overview
- 12.12.3 Debiopharm Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.12.4 Debiopharm Platinum Anti-tumor Drugs Product Portfolio
- 12.12.5 Debiopharm Recent Developments
- 12.13 ASK Pharma
- 12.13.1 ASK Pharma Company Information
- 12.13.2 ASK Pharma Business Overview
- 12.13.3 ASK Pharma Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.13.4 ASK Pharma Platinum Anti-tumor Drugs Product Portfolio
- 12.13.5 ASK Pharma Recent Developments
- 12.14 Accord Healthcare
- 12.14.1 Accord Healthcare Company Information
- 12.14.2 Accord Healthcare Business Overview
- 12.14.3 Accord Healthcare Revenue in Platinum Anti-tumor Drugs Business (2021-2026)
- 12.14.4 Accord Healthcare Platinum Anti-tumor Drugs Product Portfolio
- 12.14.5 Accord Healthcare Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst